The Avandia (rosiglitazone) debate will heat up again

January 2014

The Avandia (rosiglitazone) debate will heat up again...due to loosening of prescribing restrictions in the U.S.

This decision is based on a reanalysis of an older study that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

COPD more focus on improving management of COPD in an effort to reduce hospital admissions
Substance Use Disorder Pharmacists will play an even bigger role in preventing the misuse and abuse of opioids and other controlled drugs
Diabetes The Avandia (rosiglitazone) debate will heat up again
Diabetes Sliding scale insulin is still giving patients a ride on the blood glucose roller coaster
Dyslipidemia whether LDL goals are important for lowering cardiovascular risk
Vaccines when to recommend Prevnar 13 in ADULTS
Interactions kidney problems when clarithromycin is combined with a calcium channel blocker (amlodipine, etc)
Pediatrics using SSRIs for depression and anxiety in children and adolescents
Women's Health whether levonorgestrel emergency contraceptives (Plan B, etc) are effective in heavier women
Women's Health using ondansetron for morning sickness
Renal & Urology controversy about what works to prevent nephropathy due to contrast dyes
Healthy Lifestyles New lifestyle guidelines will help patients with New Year's resolutions to improve their health and lower cardiovascular risk